Frontiers in oncology · 2026
Assessment of treatment outcomes in patients with breast cancer who underwent mastectomy and breast reconstruction with sparing of the areola-nipple complex - single-center analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stachura Wojciech, Nowikiewicz Magdalena, Zdrenka Marek, Szymankiewicz Maria, Stachura Joanna, Głowacka-Mrotek Iwona, Tarkowska Magdalena, Szylberg Łukasz, Zegarski Wojciech, Nowikiewicz Tomasz
Аннотация
PURPOSE: Despite significant improvements in early detection of breast cancer, some patients still require mastectomy. One clinical problem currently being analyzed is the possibility of preserving the areola-nipple complex (NAC). The aim of this study was to evaluate the treatment results of breast cancer patients who underwent mastectomy with breast reconstruction with sparing of the NAC.
METHODS: 335 patients who underwent mastectomy with breast reconstruction - with sparing (group I: 300 patients) or removal of NAC (group II: 35 patients), treated in the period 07.2014-06.2020. In the study groups, the length of overall survival (OS) and recurrence-free survival (RFS) were determined - up to 24 months after the end of treatment (short-term results) and up to 80 months (long-term results). The mean follow-up time of patients was 55.6 ± 19.7 months.
RESULTS: In 50 patients (14.9%), recurrence of neoplastic disease was observed (in group I: 14.7%, in group II: 17.1%; p=0.6972). It was most often a recurrence of cancer in the scar after mastectomy - in 25 patients (respectively: 7.7% vs 5.7%; p=0.6775) or distant metastases - in 16 patients (4.0% vs 11.4%; p=0.051). A total of 10 deaths were observed (6 - 2.0% vs 4 - 11.4%; p=0.0019). A total of 37 patients (10.7% vs 14.3%) required removal of their implant, mainly due to symptoms of infection - in 24 cases (7.3% vs 5.7%).
CONCLUSION: Preserving the NAC is a safe therapeutic procedure in patients undergoing mastectomy with the option of reconstructive treatment. In both groups of patients, similar early and late treatment results were obtained.
METHODS: 335 patients who underwent mastectomy with breast reconstruction - with sparing (group I: 300 patients) or removal of NAC (group II: 35 patients), treated in the period 07.2014-06.2020. In the study groups, the length of overall survival (OS) and recurrence-free survival (RFS) were determined - up to 24 months after the end of treatment (short-term results) and up to 80 months (long-term results). The mean follow-up time of patients was 55.6 ± 19.7 months.
RESULTS: In 50 patients (14.9%), recurrence of neoplastic disease was observed (in group I: 14.7%, in group II: 17.1%; p=0.6972). It was most often a recurrence of cancer in the scar after mastectomy - in 25 patients (respectively: 7.7% vs 5.7%; p=0.6775) or distant metastases - in 16 patients (4.0% vs 11.4%; p=0.051). A total of 10 deaths were observed (6 - 2.0% vs 4 - 11.4%; p=0.0019). A total of 37 patients (10.7% vs 14.3%) required removal of their implant, mainly due to symptoms of infection - in 24 cases (7.3% vs 5.7%).
CONCLUSION: Preserving the NAC is a safe therapeutic procedure in patients undergoing mastectomy with the option of reconstructive treatment. In both groups of patients, similar early and late treatment results were obtained.